Viewpoints: Two views of Medicare equipment bidding changes; High Court case may impact FDA approval process

USA Today: Medicare Bidding Competition In Danger: Our View In 2010, Medicare spent more than $14 billion on oxygen devices, mobility scooters, diabetes test strips and other “durable medical equipment” and supplies that patients use at home. For taxpayers, and for beneficiaries with a 20% co-pay, that was about $5 billion too much. Everyone overpaid because for years, Medicare bought or rented things like this on a fee schedule set by Congress, for prices that had nothing to do with normal market competition (3/18).
USA Today: Fix The Sham Bidding Program: Opposing View In 2003, Congress required Medicare to ensure that medical equipment and supplies used by beneficiaries at home (known as “durable medical equipment,” or DME) are procured through a system that increases competition and achieves market-based prices, but doesn’t diminish quality. Unfortunately, Medicare has completely mismanaged the design and implementation of its bidding program for home oxygen equipment, power wheelchairs, diabetic supplies and other critical home medical products (Tyler J. Wilson, 3/18).
The New York Times: Drugs For Early Stage Alzheimer’s The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer’s disease, before they have developed any serious impairment or overt dementia. The goal is commendable -; to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet cause harmful side effects in people who take the medications for extended periods (3/17).
Los Angeles Times: Battle Over ‘Biosimilars’ One of the most promising frontiers in healthcare is biologic medicines -; complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called “biosimilars” (3/17).
Politico: Court Case Could Undermine Drug Approval Process On Tuesday, the Supreme Court will weigh a novel legal theory being advanced by the trial bar that, if upheld, could become the torts’ next big payday against drugmakers. The case could also undermine the basic tenets of the Food and Drug Administration’s process for approving new medicines. For this latter reason, the trial bar finds itself on the other side of the Obama administration, which has filed an amicus brief in the case (Scott Gottlieb, 3/17).
The New York Times: The Real Spending Problem [T]he taxes-versus-spending distinction is largely meaningless. Each year, the government doles out tax breaks worth $1.1 trillion. That is more than the cost of Medicare and Medicaid combined. …

Continue reading….

Content Protected Using Blog Protector By: PcDrome.
Search